Shots:

• The approval is based on P-III KEYNOTE-407 study assessing Keytruda + CT (carboplatin and either paclitaxel or nab-paclitaxel) in patients with metastatic sq. NSCLC and data from the extension of the global study in Chinese patients
• The P-III KEYNOTE-407 study results: improvement in OS and PFS; 36% reduction in risk of death; 44% reduction in risk of progression. Extension study results: 56% reduction in risk of death; improvement in PFS with a 68% reduction in risk of progression
• KEYTRUDA is an anti-PD-1 therapy- acts by blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells and is the first approved therapy in combination with CT for 1L treatment of both sq. & non sq. NSCLC in China          

Click here to­ read full press release/ article 

Ref: PRNewswire | Image: Merck